• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Redx Pharma launches third subsidiary, Redx Immunology

Redx Pharma launches third subsidiary, Redx Immunology

May 18, 2015
CenterWatch Staff

Redx Pharma has launched its third subsidiary, Redx Immunology, which will focus on developing new therapies for disorders of the immune system.

Redx Immunology will deliver up to eight new drug development candidates over the near-to-medium term for subsequent progression into clinical trials. The launch of Redx Immunology is in line with the group's strategy to develop a third therapeutic area to generate additional pipeline assets for further partnering and licensing deals. Its creation also complements Redx's current cancer-related drug programs, which encompass immuno-oncology.

Redx Immunology's approach to drug discovery and development will be consistent with the company's existing approach in its cancer and anti-infectives subsidiaries. It will focus on commercially relevant targets and seek to improve the characteristics of existing drug classes to create highly differentiated best-in-class new drugs. As with its other subsidiaries, Redx will seek partnership and license deals at an early stage in drug development programs.

Redx Immunology will operate at Redx's labs in Cheshire, U.K., and is being launched using the proceeds from the company's recent IPO, together with the matched funding from the group's $6.6 million grant award from the U.K. Government's Regional Growth Fund.

Dr. Neil Murray, chief executive of Redx Pharma, said, “Diseases involving the immune system represent some of the most defining public health challenges of the developed world. Our new R&D center for immunology will build on [our experience in] tumor immunology, where we are looking to switch on the body's immune system to attack cancer cells. Our new work in immunology will be focused around creating therapeutics that seek to turn off the immune system and tackle conditions such as inflammation and auto-immune diseases.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing